Call for Abstract
4th International Conference on Vascular Dementia, will be organized around the theme “Integrating Recent Discoveries and Interpreting Vascular Dementia Research for Better Health”
Vascular Dementia 2016 is comprised of 24 tracks and 148 sessions designed to offer comprehensive sessions that address current issues in Vascular Dementia 2016.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
Dementia is the loss of cognitive functioning, which means the loss of the ability to think, remember, or reason, as well as behavioural abilities, to such an extent that it interferes with a person’s daily life and activities.
Vascular dementia and vascular cognitive impairment (VCI) are caused by injuries to the vessels supplying blood to the brain. These disorders can be caused by brain damage from multiple strokes or any injury to the small vessels carrying blood to the brain.
- Track 1-1Stroke-related dementia
- Track 1-2Computational/ Mathematical modelling of dementia
- Track 1-3White matter and dementia
- Track 1-4Sleep and dementia
- Track 1-5Young onset dementia
- Track 1-6Multi-infarct dementia
- Track 1-7Mixed dementia
- Track 1-8Subcortical vascular dementia
- Track 1-9Post stroke dementia
- Track 1-10Parkinson dementia
Semantic dementia, which has also been called "temporal variant FTD," accounts for 20% of FTD cases. Language difficulty, the predominant complaint of people with SD, is due to the disease damaging the left temporal lobe, an area critical for assigning meaning to words. The language deficit is not in producing speech but is a loss of the meaning, or semantics, of words.
Semantic Dementia is one of the three canonical clinical syndromes associated with front temporal lobar degeneration.
- Track 2-1Mild semantic dementia
- Track 2-2Moderate semantic dementia
- Track 2-3Severe semantic dementia
- Track 2-4Clinical features of semanic dementia
- Track 2-5Causes of semantic dementia
- Track 2-6Treatment of semantic dementia
Frontotemporal dementia (frontotemporal lobar degeneration) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain, the areas generally associated with personality, behavior and language.
In frontotemporal dementia, portions of these lobes atrophy or shrink. Signs and symptoms vary, depending upon the portion of the brain affected.
- Track 3-1Behavior variant frontotemporal dementia
- Track 3-2Primary progressive aphasia
- Track 3-3Diagnosis of frontotemporal dementia
- Track 3-4Causes and risks of frontotemporal dementia
- Track 3-5Treatment of frontotemporal dementia
- Track 4-1Mild cognitive impairment
- Track 4-2Advances in mild dementia research
- Track 4-3Causes of mild dementia
- Track 4-4Mild dementia test
- Track 4-5Diagnosis of mild dementia
Severe Demnetia is the fifth stage of dementia is the most severe. At this point your loved one cannot function at all without help. They have experienced extreme memory loss. Additionally, they have no understanding of orientation in time or geography.
It is almost impossible to go out and engage in everyday activities, even with assistance. Function in the home is completely gone and help is required for attending to personal needs.
- Track 5-1Stages in severe dementia
- Track 5-2Advances in severe dementia research
- Track 5-3Severe dementia causes
- Track 5-4Severe dementia test
- Track 5-5Treatment of severe dementia
- Track 5-6Advanced therapeutics for severe dementia
Dementia is a group of symptoms that can occur as a result of some diseases that damage the brain (examples of such diseases: Alzheimer’s Disease, strokes, Fronto-Temporal Dementia, Lewy Body Dementia, etc).
The abilities of persons with dementia decline in many ways. This affects them and everyone around them–family members, friends, colleagues, etc.
- Track 6-1Pediatric dementia
- Track 6-2End of life care and grief in dementia
- Track 6-3Advance Care Planning
- Track 6-4Music Therapy in Dementia
- Track 6-5Role of dietry nitrates
- Track 6-6Advances in neuropharmacology in brain protection and recovery
- Track 6-7Advanced researches for dementia care
- Track 6-8Natural remedies for the treatment
- Track 6-9Palliative care in vascular dementia
- Track 6-10Malnutrition, undernutrition and obesity in dementia
- Track 6-11Nutritional factors and dementia
- Track 6-12Admiral Nursing
- Track 6-13Antipsychotic medications
- Track 6-14Betrothal therapy
Dementia with Lewy bodies (DLB), also known under a variety of other names including Lewy body dementia (LBD), diffuse Lewy body disease, cortical Lewy body disease, and senile dementia of Lewy type, is a type of dementia closely associated with Parkinson's disease.
It is characterized anatomically by the presence of Lewy bodies, clumps of alpha-synuclein and ubiquitin protein in neurons, detectable in post mortem brain histology. Lewy body dementia affects 1.3 million individuals in the United States alone.
- Track 7-1Lewy body disorders
- Track 7-2Muscle rigidity
- Track 7-3Neurotransmitter abnormalities
- Track 7-4Symptoms of lewy body dementia
- Track 7-5Causes of lewy body dementia
- Track 7-6Management of lewy body dementia
- Track 7-7Advances in lewy body dementia research
Vascular dementia is the second most common type of dementia (after Alzheimer's disease), affecting around 150,000 people in the UK.
The word dementia describes a set of symptoms that can include memory loss and difficulties with thinking, problem-solving or language. In vascular dementia, these symptoms occur when the brain is damaged because of problems with the supply of blood to the brain.
- Track 8-1Vascular dementia prognosis
- Track 8-2Senile dementia
- Track 8-3Senelity
- Track 8-4Cognitive impairment
- Track 8-5Advances in vascular dementia cognitive impairment treatment
A range of tests and diagnostic procedures is needed to diagnose dementia, but there are several that are fairly commonly used to diagnose dementia.
Tests can help the doctor learn whether dementia is caused by a treatable condition. Even for those dementias that cannot be reversed, knowing the type of dementia a person has can help the doctor prescribe medicines or other treatments that may improve mood and behavior and help the family.
- Track 9-1Diagnosis of vascular dementia
- Track 9-2Advances in the field of imaging
- Track 9-3MR spectroscopy
- Track 9-4EEG and brain mapping
- Track 9-5Positron emission tomography
- Track 9-6Hippocampal diffusion tensor imaging
- Track 9-7Radiology
- Track 9-8Diffusion kurtosis imaging
- Track 9-9Amyloid and tau imaging
- Track 9-10Biomarkers
- Track 9-11Neuroimaging
- Track 9-12Vascular dementia test
- Track 9-13Role of neurosonsology
Progressive dementia, which is dementia that gets worse with time, is the most common type. Five stages of progressive dementia have been outlined. They are part of the Clinical Dementia Rating (CDR), which professionals use to evaluate the progression of symptoms in patients with dementia.
The five stages describe a patient’s ability to perform in six different areas of cognition and functioning: orientation, memory, judgment, home and hobbies, personal care, and community.
- Track 10-1Early dementia
- Track 10-2Moderate dementia
- Track 10-3Advanced dementia
- Track 10-4Test of dementia stages
- Track 10-5Advances in research of dementia stages
Lewy bodies are also found in other brain disorders, including Alzheimer's disease and Parkinson's disease dementia.
Many people with Parkinson's eventually develop problems with thinking and reasoning, and many people with DLB experience movement symptoms, such as hunched posture, rigid muscles, a shuffling walk and trouble initiating movement.
- Track 11-1Cognitive problems
- Track 11-2Movement disorders
- Track 11-3Depression and lewy body dementia
- Track 11-4Lewy body dementia test
- Track 11-5Disruption of the autonomic nervous system
- Track 11-6Early stages of lewy body dementia
- Track 11-7End stage of lew body dementia
- Track 11-8Advances in lewy body dementia treatment
Frontotemporal dementia (frontotemporal lobar degeneration) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain — the areas generally associated with personality, behavior and language.
In frontotemporal dementia, portions of these lobes atrophy or shrink. Signs and symptoms vary, depending upon the portion of the brain affected. Some people with frontotemporal dementia undergo dramatic changes in their personality and become socially inappropriate, impulsive or emotionally indifferent, while others lose the ability to use language.
- Track 12-1Frotal lobed dementia
- Track 12-2Frontal lobed dementia stage
- Track 12-3Frontal lobed dementia life expectancies
- Track 12-4Frontal dementia test
- Track 12-5Advances in frontal dementia research
- Track 12-6Frontal dementia treatment
Alcohol-related dementia is a broad term currently preferred among medical professionals.
Many experts use the terms alcohol (or alcoholic) dementia to describe a specific form of ARD, characterized by impaired executive function (planning, thinking, and judgment).
Another form of ARD is known as wet brain (Wernicke-Korsakoff syndrome), characterized by short term memory loss and thiamine (vitamin B1) deficiency. ARD patients often have symptoms of both forms, i.e. impaired ability to plan, apathy, and memory loss. ARD may occur with other forms of dementia (mixed dementia). The diagnosis of ARD is widely recognized but rarely applied, due to a lack of specific diagnostic criteria.
- Track 13-1Wernicke-Korsakoff Syndrome
- Track 13-2Causes of alcoholic dementia
- Track 13-3Alcoholic dementia test
- Track 13-4Treatment for alcoholic dementia
- Track 13-5Advances in the prevention of alcoholic dementia
Diagnosing dementia is often difficult, particularly in the early stages. The GP is the first person to consult. The GP may then refer the person being diagnosed to a specialist such as a consultant.
Assessments can include conversations with the person being diagnosed and those close to them, a physical examination, memory tests and/or brain scans.
The Mini Mental State Examination (MMSE) is the most commonly used test for complaints of memory problems or when a diagnosis of dementia is being considered.
- Track 14-1 Mini Mental State Examination
- Track 14-2Blood tests for dementia
- Track 14-3Dementia brain scans
- Track 14-4Cognitive testing
- Track 14-5Neuropsychological testing
- Track 14-6Radiological tests
- Track 14-7Brain imaging techniques
Vascular disease is mainly caused by hardening of the arteries (atherosclerosis) due to a thickening of the artery lining from fatty deposits or plaques (atheroma).
Vascular disease may manifest acutely when thrombi, emboli, or acute trauma compromises perfusion. Thrombosis are often of an athermanous nature and occur in the lower extremities more frequently than in the upper extremities. Multiple factors predispose patients for thrombosis. These factors include sepsis, hypotension, low cardiac output, aneurysms, aortic dissection, bypass grafts, and underlying atherosclerotic narrowing of the arterial lumen.
- Track 15-1Peripheral artery disease
- Track 15-2Aneurysm
- Track 15-3Amyloid cascade and tau pathology
- Track 15-4Vascular pathology in aging brain
- Track 15-5Protein trafficking and synaptic pathology
- Track 15-6White matter pathology in vascular cogitive disease
- Track 15-7Hippocampal pathology in aged
- Track 15-8Retinal pathology in susac syndrome
- Track 15-9Cerebral amyloid angiopathy
Admiral Nurses are specialist dementia nurses who give much-needed practical and emotional support to family carers, as well as the person with dementia.
To offer support to families throughout their experience of dementia that is tailored to their individual needs and challenges.
To provide families with the knowledge to understand the condition and its effects, the skills and tools to improve communication, and provide emotional and psychological support to help family carers carry on caring for their family member.
- Track 16-1Primary mental health care and nursing
- Track 16-2Assessment and evaluation of mental health
- Track 16-3Cognitive behavioral therapy and family therapy in nursing
- Track 16-4Stress and emotional treatment studies and outcomes
Almost 40 per cent of people over the age of 65 experience some form of memory loss. When there is no underlying medical condition causing this memory loss, it is known as "age-associated memory impairment," which is considered a part of the normal aging process.
Brain diseases like Alzheimer’s disease and other dementias are different.
Age-associated memory impairment and dementia can be told apart in a number of ways.
- Track 17-1Brain ageing and dementia
- Track 17-2Risk factors of cognitive decline
- Track 17-3Normal ageing and dementia
- Track 17-4Neuro-anatomical changes in ageing
- Track 17-5Functional imaging test
- Track 17-6Advances of research in ageing and dementia
National Plan to Address Alzheimer’s Disease, a national effort to expand research in Alzheimer’s and related dementias prevention and treatment and to move the most promising drugs from discovery into clinical trials.
The Plan aims to prevent and effectively treat Alzheimer’s and related dementias by 2025. Its foundation is the 2011 National Alzheimer’s Project Act (NAPA), which was developed to create and maintain a national strategy to overcome the disease.
- Track 18-1Future development of therapies
- Track 18-2Aerobic exercise program
- Track 18-3Research in induced pluripotent stem cells
- Track 18-4Researches in amyloid and tau proteins
- Track 18-5Digital engagement for people with dementia
Rapidly progressive dementias (RPDs) are neurological conditions that develop subacutely over weeks to months, or rarely acutely over days. In contrast to most dementing conditions that take years to progress to death, RPD can be quickly fatal. It is critical to evaluate the RPD patient without delay, usually in a hospital setting, as they may have a treatable condition.
- Track 19-1Progressive dementias
- Track 19-2Degenerative dementias
- Track 19-3Prion diseases
- Track 19-4Chronic degenerative dementias
- Track 19-5Autoimmune encephalopathies
- Track 19-6Delirium and dementia
- Track 19-7Advances in sudden dementia research
The mainstay of management of vascular dementia is the prevention of new strokes. This includes administering antiplatelet drugs and controlling major vascular risk factors.
Neuroprotective drugs such as nimodipine, propentofylline, and posatirelin are currently under study and may be useful for vascular dementia.
- Track 22-1Omentum in the treatment of vascular dementia
- Track 22-2Cholinisterase inhibitors
- Track 22-3Impact of treatment with N-Acetylcysteine
- Track 22-4Oral redox polymer therapeutics
- Track 22-5Snoezellen and Multi sensory stimulation
- Track 22-6Effect of thioctic and enantiomers
- Track 22-7Role of phospholipids
- Track 22-8Effects of brain afobazole
Brain is an intangible conundrum which buries millions and millions of memories.
Entrepreneurship is the process of designing a new business, i.e. a startup company offering a product, process or service.
We are convinced that these new approaches to entrepreneurship research will have high impact and will lead to some of the most exciting and best publications in the years to come.
Bringing these new approaches together in one track will provide a forum for some of the best scholars in the field to join Vascular Dementia Conference 2016 and it will provide the audience with a look into the future of entrepreneurship research.
- Track 24-1Simulation semantics
- Track 24-2Cognitive science
- Track 24-3Computational theory of mind
- Track 24-4Next generation of entrepreneurs in neuroscience
- Track 24-5Neuroscience and brain game
- Track 24-6Neuromanagement
- Track 24-7Neuro-industrial-engineering